| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, |
| 24 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France |
| 21 May 2026 |
8-K: Results of Operations and Financial Condition
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq |
| 11 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
1.1 Place of Meetings. All meetings of stockholders shall be held at such place, if any, as may be designated from time to time by the Board of Directors, the Chair of the Board or the Chief Executive Officer or, if not so designated, at... |
Loading...